Buprenorphine misinformation and willingness to treat patients with opioid use disorder among primary care-aligned health care professionals
Abstract Background Buprenorphine is a highly effective medication for opioid use disorder that is underused by health care professionals (HCPs). Medications for opioid use disorder (MOUD) misinformation may be an important barrier to buprenorphine access, but most implementation strategies have aim...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-01-01
|
| Series: | Addiction Science & Clinical Practice |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13722-024-00436-y |
| _version_ | 1827377216805142528 |
|---|---|
| author | Berkeley Franz Lindsay Y. Dhanani O. Trent Hall Daniel L. Brook Cheyenne Fenstemaker Janet E. Simon William C. Miller |
| author_facet | Berkeley Franz Lindsay Y. Dhanani O. Trent Hall Daniel L. Brook Cheyenne Fenstemaker Janet E. Simon William C. Miller |
| author_sort | Berkeley Franz |
| collection | DOAJ |
| description | Abstract Background Buprenorphine is a highly effective medication for opioid use disorder that is underused by health care professionals (HCPs). Medications for opioid use disorder (MOUD) misinformation may be an important barrier to buprenorphine access, but most implementation strategies have aimed to reduce negative attitudes towards patients with opioid use disorder (OUD) rather than misinformation specific to buprenorphine use. In this study, we assessed the degree to which HCPs endorsed misinformation related to buprenorphine, and whether this is associated with willingness to provide care to patients with OUD. Methods In September-December of 2022, we surveyed HCPs practicing in Ohio (n = 409). Our primary outcomes included a previously validated 5-item measure of HCP willingness to treat patients with OUD, and three other measures of willingness. Our key independent variable was a study-developed 5-item measure of endorsement of misinformation related to buprenorphine, which assessed beliefs in buprenorphine’s efficacy in managing withdrawal symptoms and reducing overdose deaths as well as beliefs about the role of buprenorphine in achieving remission. We computed descriptive and bivariable statistics and fit regression models predicting each outcome of interest. Results On average, HCPs scored 2.34 out of 5.00 (SD = 0.80) on the composite measure of buprenorphine misinformation. 48.41% of participants endorsed at least one piece of misinformation. The most endorsed items were that buprenorphine is ineffective at reducing overdose deaths (M = 2.75, SD =0 .98), and that its use substitutes one drug for another (M = 2.41, SD = 1.25). HCP endorsement of buprenorphine misinformation significantly and negatively predicted willingness to work with patients with OUD (b = − 0.34; 95% CI − 0.46, − 0.21); intentions to increase time spent with this patient population (b = − 0.36; 95% CI − 5.86, − 1.28); receipt of an X-waiver (OR = 0.54, 95% CI 0.38, 0.77); and intention to get an X-waiver (OR: 0.56; 95% CI: 0.33−0.94). Conclusions Misinformation is common among HCPs and associated with lower willingness to treat patients with OUD. Implementation strategies to increase MOUD use among HCPs should specifically counter misinformation related to buprenorphine. Clinical Trial Registration: Clinicaltrials.gov, NCT05505227. Registered 17 August 2022, https://clinicaltrials.gov/ct2/show/NCT05505227 |
| first_indexed | 2024-03-08T12:35:50Z |
| format | Article |
| id | doaj.art-cf22780368ff40e8be743bdc2d78fba7 |
| institution | Directory Open Access Journal |
| issn | 1940-0640 |
| language | English |
| last_indexed | 2024-03-08T12:35:50Z |
| publishDate | 2024-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Addiction Science & Clinical Practice |
| spelling | doaj.art-cf22780368ff40e8be743bdc2d78fba72024-01-21T12:29:45ZengBMCAddiction Science & Clinical Practice1940-06402024-01-011911910.1186/s13722-024-00436-yBuprenorphine misinformation and willingness to treat patients with opioid use disorder among primary care-aligned health care professionalsBerkeley Franz0Lindsay Y. Dhanani1O. Trent Hall2Daniel L. Brook3Cheyenne Fenstemaker4Janet E. Simon5William C. Miller6Ohio University Heritage College of Osteopathic Medicine, Department of Social Medicine, Ohio University AthensRutgers University School of Management and Labor RelationsDepartment of Psychiatry and Behavioral Health, Ohio State University Wexner Medical CenterOhio State University College of Public HealthOhio University Heritage College of Osteopathic Medicine, Department of Social Medicine, Ohio University AthensOhio University College of Health Sciences and ProfessionsGillings School of Public Health , University of North Carolina-Chapel HillAbstract Background Buprenorphine is a highly effective medication for opioid use disorder that is underused by health care professionals (HCPs). Medications for opioid use disorder (MOUD) misinformation may be an important barrier to buprenorphine access, but most implementation strategies have aimed to reduce negative attitudes towards patients with opioid use disorder (OUD) rather than misinformation specific to buprenorphine use. In this study, we assessed the degree to which HCPs endorsed misinformation related to buprenorphine, and whether this is associated with willingness to provide care to patients with OUD. Methods In September-December of 2022, we surveyed HCPs practicing in Ohio (n = 409). Our primary outcomes included a previously validated 5-item measure of HCP willingness to treat patients with OUD, and three other measures of willingness. Our key independent variable was a study-developed 5-item measure of endorsement of misinformation related to buprenorphine, which assessed beliefs in buprenorphine’s efficacy in managing withdrawal symptoms and reducing overdose deaths as well as beliefs about the role of buprenorphine in achieving remission. We computed descriptive and bivariable statistics and fit regression models predicting each outcome of interest. Results On average, HCPs scored 2.34 out of 5.00 (SD = 0.80) on the composite measure of buprenorphine misinformation. 48.41% of participants endorsed at least one piece of misinformation. The most endorsed items were that buprenorphine is ineffective at reducing overdose deaths (M = 2.75, SD =0 .98), and that its use substitutes one drug for another (M = 2.41, SD = 1.25). HCP endorsement of buprenorphine misinformation significantly and negatively predicted willingness to work with patients with OUD (b = − 0.34; 95% CI − 0.46, − 0.21); intentions to increase time spent with this patient population (b = − 0.36; 95% CI − 5.86, − 1.28); receipt of an X-waiver (OR = 0.54, 95% CI 0.38, 0.77); and intention to get an X-waiver (OR: 0.56; 95% CI: 0.33−0.94). Conclusions Misinformation is common among HCPs and associated with lower willingness to treat patients with OUD. Implementation strategies to increase MOUD use among HCPs should specifically counter misinformation related to buprenorphine. Clinical Trial Registration: Clinicaltrials.gov, NCT05505227. Registered 17 August 2022, https://clinicaltrials.gov/ct2/show/NCT05505227https://doi.org/10.1186/s13722-024-00436-yOpioid-related disordersPrimary careMisinformationBuprenorphineAddiction medicine |
| spellingShingle | Berkeley Franz Lindsay Y. Dhanani O. Trent Hall Daniel L. Brook Cheyenne Fenstemaker Janet E. Simon William C. Miller Buprenorphine misinformation and willingness to treat patients with opioid use disorder among primary care-aligned health care professionals Addiction Science & Clinical Practice Opioid-related disorders Primary care Misinformation Buprenorphine Addiction medicine |
| title | Buprenorphine misinformation and willingness to treat patients with opioid use disorder among primary care-aligned health care professionals |
| title_full | Buprenorphine misinformation and willingness to treat patients with opioid use disorder among primary care-aligned health care professionals |
| title_fullStr | Buprenorphine misinformation and willingness to treat patients with opioid use disorder among primary care-aligned health care professionals |
| title_full_unstemmed | Buprenorphine misinformation and willingness to treat patients with opioid use disorder among primary care-aligned health care professionals |
| title_short | Buprenorphine misinformation and willingness to treat patients with opioid use disorder among primary care-aligned health care professionals |
| title_sort | buprenorphine misinformation and willingness to treat patients with opioid use disorder among primary care aligned health care professionals |
| topic | Opioid-related disorders Primary care Misinformation Buprenorphine Addiction medicine |
| url | https://doi.org/10.1186/s13722-024-00436-y |
| work_keys_str_mv | AT berkeleyfranz buprenorphinemisinformationandwillingnesstotreatpatientswithopioidusedisorderamongprimarycarealignedhealthcareprofessionals AT lindsayydhanani buprenorphinemisinformationandwillingnesstotreatpatientswithopioidusedisorderamongprimarycarealignedhealthcareprofessionals AT otrenthall buprenorphinemisinformationandwillingnesstotreatpatientswithopioidusedisorderamongprimarycarealignedhealthcareprofessionals AT daniellbrook buprenorphinemisinformationandwillingnesstotreatpatientswithopioidusedisorderamongprimarycarealignedhealthcareprofessionals AT cheyennefenstemaker buprenorphinemisinformationandwillingnesstotreatpatientswithopioidusedisorderamongprimarycarealignedhealthcareprofessionals AT janetesimon buprenorphinemisinformationandwillingnesstotreatpatientswithopioidusedisorderamongprimarycarealignedhealthcareprofessionals AT williamcmiller buprenorphinemisinformationandwillingnesstotreatpatientswithopioidusedisorderamongprimarycarealignedhealthcareprofessionals |